Alnylam: KARDIA-1 Phase 2 Dose-Ranging Study Of Zilebesiran Meets Primary Endpoint

Logo NasdaqNasdaq
2023-09-07 12:12:40  • 2 mins

(RTTNews) - RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (ALNY) announced Thursday positive topline results from the KARDIA-1 Phase 2 study of zilebesiran.

zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen or AGT in development for the treatment of hypertension in patients at high cardiovascular risk.

The KARDIA-1 Phase 2 trial is a randomized, double-blind, placebo-controlled, multi-center global dose-ranging study designed to evaluate the efficacy and safety of zilebesiran as monotherapy in adults with mild-to-moderate hypertension.

Continue read on nasdaq.com

A doctor working for the US government visited the Wuhan facility which has faced questions over the origins of Covid-19 and raised safety concerns almost...
Logo Daily MailDaily Mail
2023-09-22 23:40:57  • 1 min
Astrazeneca shares rose after a positive trial of a drug for a common type of breast cancer. The study found datopotamab deruxtecan showed a 'statistically...
Logo Daily MailDaily Mail
2023-09-22 20:50:11  • 1 min
PSV will take on Almere in an Eredivisie fixture at the Yanmar Stadium on Saturday. The hosts, who finished runners-up in the league last season, will be...
Logo GoalGoal
2023-09-23 12:00:02  • 1 min
Expert recap and game analysis of the Al Ahli vs. Al Nassr Saudi Pro League game from September 22, 2023 on ESPN.
Logo ESPNESPN
2023-09-22 20:30:50  • 1 min
The European Commission has approved ViiV Healthcare's Apretude (cabotegravir long-acting (LA) injectable and tablets) for HIV prevention. Cabotegravir is...
Logo BenzingaBenzinga
2023-09-19 13:20:36  • 1 min
The Biden administration has officially barred taxpayer dollars from being funneled to a controversial Chinese lab long suspected of causing the Covid...
Logo Daily MailDaily Mail
2023-09-21 15:47:40  • 1 min
Valencia coach Ruben Baraja is eager for them to maintain momentum against Alaves today. Los Che go into the game on the back of a stunning win against...
(RTTNews) - Seagen Inc. (SGEN) and Astellas Pharma Inc. reported positive topline results from the Phase 3 EV-302 trial for PADCEV in combination with...
Logo NasdaqNasdaq
2023-09-22 09:51:30  • 1 min
Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals ( NASDAQ:AUPH ) with a Buy recommendation....
Logo NasdaqNasdaq
2023-09-22 21:51:00  • 1 min
Health care stocks were slightly higher late Friday afternoon with the NYSE Health Care Index up 0.1% and the Health Care Select Sector SPDR Fund (XLV)...
Logo NasdaqNasdaq
2023-09-22 19:48:37  • 1 min
Pirola may pose no more reason for concern than the swathe of other Covid variants that are spreading, UK Health Security Agency (UKHSA) scientists have...
Intellia Therapeutics (NASDAQ: NTLA) and Rocket Pharmaceuticals (NASDAQ: RCKT) are gene-editing biotechs that want to offer what few others can: cures for...
(RTTNews) - Merck & Co Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Friday positive topline results from the Phase 3 KEYNOTE-A39...
Logo NasdaqNasdaq
2023-09-22 10:59:35  • 1 min
What happened New analyst takes on Azul (NYSE: AZUL) this week gave the company's stock a decent lift. Across that stretch of time, as data compiled by...
Logo NasdaqNasdaq
2023-09-22 22:45:31  • 1 min
For Immediate Release Chicago, IL September 19, 2023 Today, Zacks Equity Research discusses Corcept Therapeutics CORT, Aurinia Pharmaceuticals AUPH, Alpine...
The buzz among investors has been on the rise after a study showed obesity drug Wegovy reduced the risks of heart attacks and strokes.
Logo FortuneFortune
2023-09-22 21:19:39  • 1 min
Arsenal have dropped a hint that Oleksandr Zinchenko will start against Tottenham on Sunday after the Ukrainian was placed on their 'next' game social media...
Logo The MirrorThe Mirror
2023-09-22 20:11:21  • 1 min
(RTTNews) - Merck (MRK) and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, plus LENVIMA, the orally...
Logo NasdaqNasdaq
2023-09-22 12:14:13  • 1 min
On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's ALNY patisiran. It has a favorable benefit-risk profile in...
Logo BenzingaBenzinga
2023-09-14 11:26:46  • 1 min
Health care stocks were steady pre-bell Friday, with the Health Care Select Sector SPDR Fund ( XLV ) and iShares Biotechnology ETF ( IBB ) recently...
Logo NasdaqNasdaq
2023-09-22 13:13:28  • 1 min